PMID- 33539990
OWN - NLM
STAT- MEDLINE
DCOM- 20211123
LR  - 20211123
IS  - 1916-7075 (Electronic)
IS  - 0828-282X (Linking)
VI  - 37
IP  - 7
DP  - 2021 Jul
TI  - The Role of Extravalvular Cardiac Damage Staging in Aortic Valve Disease 
      Management.
PG  - 1004-1015
LID - S0828-282X(21)00065-9 [pii]
LID - 10.1016/j.cjca.2021.01.020 [doi]
AB  - Current management of patients with aortic valve disease, including aortic valve 
      stenosis (AS), aortic valve regurgitation (AR), and mixed aortic valve disease 
      (MAVD), remains challenging. American and European guideline recommendations 
      regarding the timing of intervention are mainly based on the assessment of 
      disease severity (ie, grading), presence of symptoms related to aortic valve 
      disease, left ventricular systolic dysfunction, or LV enlargement. Furthermore, 
      the decision regarding the type of intervention (ie, surgical vs transcatheter) 
      is primarily based on risk assessment from surgical risk scores. There is, 
      however, less emphasis on the importance of the assessment of anatomic and 
      functional cardiac repercussions of aortic valve disease to guide the clinical 
      management of these patients. Recently, a novel approach has been proposed to 
      improve the management of aortic valve disease with 2 main components for risk 
      stratification of the disease: 1) grading the severity of aortic valve disease, 
      and 2) staging the extent of extravalvular cardiac damage associated with aortic 
      valve disease with the use of echocardiography. To date, this novel approach of 
      extravalvular cardiac damage staging was proposed and validated only in the 
      context of AS but could be extended to other valvular heart diseases, including 
      AR and MAVD. Further studies are also needed to test the incremental value of 
      additional imaging parameters (eg, myocardial fibrosis by magnetic resonance) as 
      well as blood biomarkers (eg, natriuretic peptide, cardiac troponin, and others) 
      to the existing cardiac damage staging schemes.
CI  - Copyright (c) 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All 
      rights reserved.
FAU - Tastet, Lionel
AU  - Tastet L
AD  - Institut universitaire de cardiologie et de pneumologie de Quebec-Universite 
      Laval, Quebec City, Quebec, Canada.
FAU - Genereux, Philippe
AU  - Genereux P
AD  - Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New 
      Jersey, USA; Clinical Trials Center, Cardiovascular Research Foundation, New 
      York, New York, USA; Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada.
FAU - Bernard, Jeremy
AU  - Bernard J
AD  - Institut universitaire de cardiologie et de pneumologie de Quebec-Universite 
      Laval, Quebec City, Quebec, Canada.
FAU - Pibarot, Philippe
AU  - Pibarot P
AD  - Institut universitaire de cardiologie et de pneumologie de Quebec-Universite 
      Laval, Quebec City, Quebec, Canada. Electronic address: 
      philippe.pibarot@med.ulaval.ca.
LA  - eng
GR  - FDN-143225/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210201
PL  - England
TA  - Can J Cardiol
JT  - The Canadian journal of cardiology
JID - 8510280
SB  - IM
MH  - *Aortic Valve Disease/classification/complications/diagnosis/surgery
MH  - *Diagnostic Techniques, Cardiovascular
MH  - *Heart Diseases/diagnosis/etiology/therapy
MH  - Humans
MH  - Risk Adjustment/*methods
MH  - Risk Assessment/methods
MH  - Severity of Illness Index
MH  - Time-to-Treatment
EDAT- 2021/02/05 06:00
MHDA- 2021/11/24 06:00
CRDT- 2021/02/04 20:13
PHST- 2020/12/01 00:00 [received]
PHST- 2021/01/19 00:00 [revised]
PHST- 2021/01/22 00:00 [accepted]
PHST- 2021/02/05 06:00 [pubmed]
PHST- 2021/11/24 06:00 [medline]
PHST- 2021/02/04 20:13 [entrez]
AID - S0828-282X(21)00065-9 [pii]
AID - 10.1016/j.cjca.2021.01.020 [doi]
PST - ppublish
SO  - Can J Cardiol. 2021 Jul;37(7):1004-1015. doi: 10.1016/j.cjca.2021.01.020. Epub 
      2021 Feb 1.